Skip to main content
SpringerLink
Log in

Clinical update on the use of recombinant factor VII

  • Chapter
Inhibitors to Coagulation Factors

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 386))

Abstract

Much effort has converged on finding an agent capable of activating the final common pathway of the coagulation cascade inducing hemostasis independently of factor VIII (F.VIII) or factor IX (RIX). Such an agent should be not only hemostatically active but also safe with respect to thromboembolic complications. Factor Vila (F.VIIa) becomes proteolytically active when complexed with tissue factor or other phopholipids minimizing the risk of inducing systemic activation of the coagulation system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. U. Hedner, W. Kisiel, Use of human factor Vila in treatment of two haemophilia A patients with high-titer inhibitors, J Clin Invest. 71: 1836 (1983).

    Article  PubMed  CAS  Google Scholar 

  2. . U. Hedner, S. Bjoern, S.S. Bernvil, L. Tengborn, L. Stigendahl, Clinical experience with human plasma-derived factor Vila in patients with hemophilia A and high-titer inhibitors, Haemostasis. 19: 335 (1989).

    PubMed  CAS  Google Scholar 

  3. F.S, Hagen, CL. Gray, P. O’Hara, FJ. Grant, G.C. Saari, R.G. Woodbury, CE. Hart, M. Insley, W. Kisiel, K. Kurachi, E.W. Davie, Characterization of a cDNA coding for human factor VII, Proc Nat’l Acad Sci USA. 83: 2413 (1986).

    Google Scholar 

  4. . L. Thim, S. Bjoern, M. Christensen, E.M. Nicolaisen, T. Lund-Hansen, AH. Pedersen, U. Hedner, Amino acid sequence and posttranslational modifications of human factor Vila from plasma and transfected baby hamster kidney cells. Biochemistry. 27: 7785 (1988).

    Article  PubMed  CAS  Google Scholar 

  5. U. Hedner, T. Lund-Hansen, D. Winther, Comparison of the effect of factor VII prepared from human plasma and recombinant Vila in vitro and in rabbits, Thromb Haemost. 58: 270a (1987).

    Google Scholar 

  6. U. Hedner, J. Ljungberg, T. Lund-Hansen, Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model, Blood and Fibrinol. 1: 145 (1990).

    CAS  Google Scholar 

  7. K.M. Brinkhous, U. Hedner, J.B. Garrís, V. Diness, M.S. Read, Effect of recombinant factor Vila on the hemostatic defect in dogs with hemophilia, hemophilia B, and von Willebrand disease, Proc Natl Acad Sci USA. 86: 1382 (1989).

    Article  PubMed  CAS  Google Scholar 

  8. . S.I. Rapaport, Inhibition of factor Vila/tissue factor-induced blood coagulation: With particular emphasis upon a factor Xa-dependent inhibitory mechanism, Blood73: 359 (1989).

    PubMed  CAS  Google Scholar 

  9. U. Hedner, S. Schulman, K.A. Alberts, M. Blomback, H. Johnsson, S. Glazer, K. Pingel, Successful use of rFVIIa in a patient with severe hemophilia A subjected to synovectomy. Lancet. ii: 193 (1988).

    Google Scholar 

  10. G.B. Macik, H. Hohneker, H. Roberts, A.M. Griffin, The use of recombinant activated factor VII for treatment of a retropharyngeal haemorrhage in a hemophilic patient with a high-titer inhibitor. Am J Hematology. 32: 232 (1989).

    Article  CAS  Google Scholar 

  11. S.A. Grupp, S. Glazer, D.A. Williams, Recalcitrant epistaxis in a hemophiliac with inhibitors: Experience with recombinant factor Vila. Blood 74(Suppl 1 ): 3901 (abstract no. 1489) (1989).

    Google Scholar 

  12. M.L. Schmidt, H.E. Smith, S. Gamerman, S. Glazer, J.P. Scott, Prolonged recombinant activated factor VII (rFVIIa). Treatment for severe bleeding and surgical hemostasis in a factor-IX deficient patient with an inhibitor. Paper presented at a meeting of the Society for Pediatric Research, MA (1990).

    Google Scholar 

  13. A. Gringeri, E. Santagostino, P.M. Mannucci, Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody, Haemostasis. 21: 1 (1991).

    Google Scholar 

  14. . L. Tengborn, L. Stigendahl, P.O. Elfstrand, B. Kjellman, S. Glazer, Hemostatically effective treatment with recombinant factor Vila (rFVIIa) of a hemophiliac boy with newly developed inhibitors to factor VIII. Abstract presented at the XIX International Congress of the World Federation of Hemophilia, Washington, D.C., August 14 to 19 (1990).

    Google Scholar 

  15. M.L. Schmidt, H.E. Smith, S. Gamerman, D. DiMichele, S. Glazer, J.P. Scott, Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX deficient patient with an inhibitor, Br J Haematol. 78:460 (1991.)

    Google Scholar 

  16. U. Hedner, M. Feldstedt, S. Glazer, Recombinant FV1Ia in hemophilia treatment, in: Hemophilia and von Willebrands Disease in the 1990s, J.M. Lusher, CM. Kessler, eds., Elsevier Science Publishers B.V. (1991).

    Google Scholar 

  17. J. Ingerslev, M. Feldstedt, S. Sindet-Petersen, Control of hemostasis by recombinant factor Vila in a hemophilia A patient with inhibitors during major oral surgery. Abstract presented at the XIX International Congress of the World Federation of Hemophilia, Washington, D.C, August 14 to 19 (1990).

    Google Scholar 

  18. S.F. Stein, A. Duncan, D. Cutler, S. Glazer, Disseminated intravascular coagulation (DIC) in a hemophiliac treated with recombinant factor Vila. Abstract presented at the American Society of Hematology 32nd Annual Meeting, Boston, MA, November 28 to December 4 (1990).

    Google Scholar 

  19. U. Hedner, Factor Vila in the treatment of haemophilia, Blood Coagul Fibrinolysis. 1: 307 (1990).

    Article  PubMed  CAS  Google Scholar 

  20. B.A. Bell, K. Birch, S. Glazer, Experience with recombinant factor Vila in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement. A case report. Am J Pediatr Hematol Oncol. 15: 77 (1993).

    Article  PubMed  CAS  Google Scholar 

  21. S. Schulman, A therapeutic alternative for haemophiliacs with inhibitors. Acta Pediatr. 81, paper 926 (1992).

    Google Scholar 

  22. J. Ingerslev, L. Knudsen, S. Sindet-Petersen, Haemostatic efficacy of recombinant factor Vila in haemophilia A patients with inhibitors. Abstract presented at the XX International Congress of the World Federation of Hemophilia, Athens, Greece, October 12 to 17(1992).

    Google Scholar 

  23. J. Ingerslev, L. Knudsen, S. Sindet-Petersen, Clinical experiences with recombinant factor Vila in haemophilia A patients with inhibitors. Abstract presented at the 3rd Bari International Conference on Factor VIII/von Willebrand Factor, Foggia, Italy, June 7 to 13 (1992).

    Google Scholar 

  24. M. Makris, Recombinant factor Vila: The UK experience. Abstract presented at the 24th Congress of the International Society of Hematology, London, UK, August 23 to 27 (1992).

    Google Scholar 

  25. U. Hedner, S. Glazer, Management of hemophilia patients with inhibitors, Hematol Oncol Clin North Am6: 1035 (1992).

    PubMed  CAS  Google Scholar 

  26. M.L. Schmidt, S. Gamerman, H.E. Smith, J.P. Scott, D. DiMichelle, Recombinant activated factor VII (rFVIIa) therapy for muscle and soft tissue hemorrhage in factor VIII and IX-defìcient patients with inhibitors. Abstract presented at the 33rd Annual Meeting and Exposition of the American Society of Hematology, Denver, Colorado, December 6 to 10 (1991).

    Google Scholar 

  27. MX. Schmidt, S. Gamerman, H.E. Smith, J.P. Scott, D. DiMichelle, Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage (ICH) in hemophilia A patients with inhibitors. Abstract presented at the 33rd Annual Meeting and Exposition of the American Society of Hematology, Denver, Colorado, December 6 to 10 (1991).

    Google Scholar 

  28. D.B. Brettler, A.D. Forsberg, RH. Levine, et al, The use of porcine factor VIII concentrate (HyateiC) in the treatment of patients with inhibitor antibodies to factor FVIII, Arch Intern Med. 149: 1381 (1989).

    Article  PubMed  CAS  Google Scholar 

  29. J.M. Lusher, et al., Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII, N Eng J Med. 303: 421 (1980).

    Article  CAS  Google Scholar 

  30. L.J.M. Sjamsoedin, et al., The effect of activated prothrombin-complex concentrate (Feiba) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor Vili. A double-blind clinical trial, N Engl J Med305: 717 (1981).

    Article  PubMed  CAS  Google Scholar 

  31. J.M. Lusher, PM. Blatt, J.A. Penner, et al., Autoplex versus proplex: A controlied, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII, Blood62: 1135 (1983).

    PubMed  CAS  Google Scholar 

  32. M. Hilgartner, L. Aledort, A. Andes, J.C. Gill, Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients, Transfusion30: 626 (1990)

    Article  PubMed  CAS  Google Scholar 

  33. CK. Kasper, L. Boylen, N. Ewing, J.V. Luck, S.L. Dietrich, Hematologic management of hemophilia A for surgery, JAMA. 253: 1279 (1985).

    Article  PubMed  CAS  Google Scholar 

  34. L. Johansen, D. Bucher, L.L. Hansen, H. Kastberg, CM. Lindley, P. Madsen, W.T. Sawyer, Relation between factor Vila coagulant activity and PT and between factor Vila coagulant activity and APTT in human plasma, Abstract presented at the XlVth Congress of the International Society on Thrombosis and Hemostasis, New York, USA, July 4 - 9 (1993).

    Google Scholar 

  35. D.S.C Telgt, B.G. Macik, D.M. McCord, D.M. Monroe, H.R. Roberts, Mechanism by which recombinant factor Vila shortens the aPTT: Activation of factor X in the absence of tissue factor, Thromb Res. 56:603(1989).

    Article  PubMed  CAS  Google Scholar 

  36. I.M. Nilsson, U. Hedner, A. Ahlberg, et al.. Surgery of hemophiliacs-20 years’ experience, World J Surg. 1:55(1977).

    Article  PubMed  CAS  Google Scholar 

  37. R.P.C. Rodgers, J. Levin, A critical reappraisal of the bleeding time, Semin Thromb Hemost. 16 No.1(1990).

    Google Scholar 

  38. H.J. Weiss, B. Lages, Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds, Blood629: 635 (1988).

    Google Scholar 

  39. U. Hedner, D. Bergqvist, J. Ljungberg, B. Nilsson, Haemostatic effect of factor Vila in thrombocytopenic rabbits, Blood. 66:1043(1985).

    Google Scholar 

  40. J. Kristensen, A. Killander, E. Hippe, C. Helleberg, J. Ellegaard, M. Holm, U. Hedner, Recombinant factor Vila (rFVIIa) reduces the bleeding time in patients with thrombocytopenia, Abstract submitted to The American Society of Hematology 35th Annual Meeting, St. Louis, USA, December 3–7 (1993).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Novo Nordisk A/S Biopharmaceuticals Division, DK-2820, Gentofte, Denmark

    Steven Glazer, Ulla Hedner & Jorn F. Falch

Authors
  1. Steven Glazer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulla Hedner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jorn F. Falch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mount Sinai Medical School, New York, New York, USA

    Louis M. Aledort

  2. American Red Cross Biomedical Services, Rockville, Maryland, USA

    Leon W. Hoyer

  3. Wayne State University School of Medicine and The Children’s Hospital of Michigan, Detroit, Michigan, USA

    Jeanne M. Lusher

  4. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

    Howard M. Reisner  & Gilbert C. White II  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Plenum Press, New York

About this chapter

Cite this chapter

Glazer, S., Hedner, U., Falch, J.F. (1995). Clinical update on the use of recombinant factor VII. In: Aledort, L.M., Hoyer, L.W., Lusher, J.M., Reisner, H.M., White, G.C. (eds) Inhibitors to Coagulation Factors. Advances in Experimental Medicine and Biology, vol 386. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0331-2_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-0331-2_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-8001-6

  • Online ISBN: 978-1-4613-0331-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation